Genmab — November 2016
-
den and får godt 3 timer idag ...
-
køb en kalkun istedet
-
har du også altid en bærbar på toilettet med klistrede taster ?
-
Hvis Jan performer i dag kan han da få leveret hjemmelavet and til hoveddøren fra slagteren
-
Joakim...Hvor har du gemt dig i dag?
-
Upgradering til køb fra Zacks Investment: https://www.americanbankingnews.com/2016/11/08/genmab-as-gnmsf-upgraded-by-zacks-investment-research-to-buy.html
-
tror jeg ikke. Zachs er jo et program der blot indsamler andre analytikeres anbefalinger og indtjeningsestimater og automatisk beregninger køb og salg.
-
der er ingen menneskelige vurderinger bag
-
Kender dem ikke. Fik den via vores Facebookgruppe.
-
Fra Zacks: Genmab A/S (GNMSF - Free Report) is a biotech company that develops antibody therapeutics for the treatment of cancer internationally including the U.S. The company has a Zacks Rank #2 and a VGM Score of ‘B’. The Zacks Consensus Estimate for its current year earnings surged 109.8% over the last 60 days. The company’s expected growth rate for the next year is a whopping 224.3%.
-
-
-
ZACH duer slet ikke, spild af tid og penge
-
Gæt en gang Helge ,, i pengetanken ,, tænk hvis en andefarmer fik fat i mig idag
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind